Pmgc Holdings vs Vistagen Therapeutics
Vistagen Therapeutics is the larger business, with $1.3m of revenue in fiscal 2026 against $590,084 for Pmgc Holdings (2.2 times as much). Vistagen Therapeutics grew faster (161.1% against -65.5%). Pmgc Holdings kept more of each dollar of sales as profit: a net margin of -1313.0% against -5491.3%.
| Latest fiscal year | Pmgc HoldingsELAB, 2025 | Vistagen TherapeuticsVTGN, 2026 |
|---|---|---|
| Revenue | $590,084 | $1.3m |
| Revenue growth | -65.5% | 161.1% |
| Net income | −$7.7m | −$69.7m |
| Operating margin | — | — |
| Net margin | -1313.0% | -5491.3% |
| Return on equity | -132.8% | -131.6% |
| Free cash flow | −$6.4m | −$66.4m |
| Cash | $5.4m | $30.8m |
| Total debt | $1.4m | $96,000 |
| Debt to equity | 18.2% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 32 | 41 |
| Market value | $12.0m | $7.3m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |